Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai to present new Halaven data at SABCS 2013

Eisai to present new Halaven data at SABCS 2013

5th December 2013

Eisai will be sharing the latest clinical findings on its novel anticancer agent Halaven at a symposium in San Antonio, Texas from December 10th to 14th 2013.

The firm will attend the San Antonio Breast Cancer Symposium (SABCS) in order to give four presentations detailing the performance of Halaven in a number of different patient indications.

One poster session will examine the effect of post-progression anti-cancer treatments and metastatic progression events on overall survival rates among patients receiving Halaven therapy for metastatic breast cancer, while another will assess the tolerability and efficacy of the drug.

Eisai will also share data from a phase II trial testing Halaven as a specific therapy for HER2-negative breast cancer.

A company statement said: "The studies reflect Eisai's current and ongoing research efforts to establish the clinical benefits of Halaven and maximise the drug's value."

This comes after the firm applied for European approval of Halaven in an expanded indication, allowing it to be used in earlier-line treatment of patients with metastatic breast cancer.ADNFCR-8000103-ID-801669051-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.